View Older Stories View More Recent Stories

Sep 8, 2020 06:31AM Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
Sep 8, 2020 06:31AM Biopharma Leaders Unite to Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite To Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 01:00AM Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
Jul 21, 2020 07:30AM Acerus Announces Addition of Chief Medical Officer
Jul 2, 2020 04:30PM Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Jun 23, 2020 12:59AM Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
Jun 19, 2020 07:32AM Regeneron (REGN), Sanofi (SNY) announce Dupixent approved in China for adults with moderate-to-severe atopic dermatitis
Jun 19, 2020 07:30AM Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
Jun 15, 2020 12:48PM Santander's U.S. unit to close offices on June 19 commemorating Juneteenth
May 29, 2020 08:00AM Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
May 26, 2020 11:40AM Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
May 22, 2020 06:25PM Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
May 5, 2020 01:00AM Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma
Apr 27, 2020 07:00AM Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
Apr 27, 2020 06:58AM Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
Apr 3, 2020 01:00AM Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
Mar 30, 2020 01:00AM Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Mar 27, 2020 02:00AM Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
Mar 27, 2020 02:00AM Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19
Jan 28, 2020 01:00AM Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
Dec 10, 2019 08:31AM Sanofi (SNY) and Regeneron (REGN) to restructure Antibody collaboration for Kevzara and Praluent
Dec 10, 2019 08:30AM Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Oct 29, 2019 08:15AM Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
Sep 20, 2019 06:48AM Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
Sep 16, 2019 01:00AM Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
Aug 28, 2019 04:35PM Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
Aug 6, 2019 01:05AM Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Aug 6, 2019 01:00AM Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
Jul 1, 2019 10:00AM Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
Jun 28, 2019 07:00AM Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Jun 26, 2019 01:30PM Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Jun 26, 2019 01:30PM FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Jun 21, 2019 01:00AM Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
May 21, 2019 08:00AM Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
May 7, 2019 09:01AM Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Apr 26, 2019 07:21PM Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
Apr 26, 2019 11:16AM CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
Mar 15, 2019 07:40PM Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Mar 11, 2019 03:45PM FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mar 8, 2019 01:02AM Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Mar 1, 2019 08:14AM Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
Feb 25, 2019 12:46PM Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 11, 2019 07:00AM Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 4, 2019 01:01AM Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Jan 7, 2019 02:31AM Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Dec 3, 2018 01:32PM BIVV001 Phase 1/2a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A
Dec 1, 2018 12:00PM At ASH, Extended Half-Life Therapies ELOCTATE® and ALPROLIX® Demonstrate Proven Efficacy and Well-Characterized Safety over Four Years
Nov 11, 2018 08:17AM Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
View More Recent Stories View Older Stories